[Combined chemotherapy of ovarian cancer with special reference to carboquone].
Carboquone (CQ) was administered to 20 patients with ovarian cancer as a main drug in the multiple chemotherapy. Picibanil and Futraful (FT-207) were medicated simultaneously. CQ was given 3 mg each, 2 times a week, up to total 30 mg intravenously or intraperitoneally. 1) The effect of CQ was evaluated in 6 cases. The response was good in 2 cases, fair in 3, and poor in 1. In the other 3 cases after surgery long-lasting remission suggested the effectiveness of this drug. 2) When compared with 43 cases of control group(historical control), apparent higher survival rate was observed until 3 years in this group. 3) Side effects were noted in 89% of the patients. In 5 patients CQ treatment was discontinued because of severe complications. These complications were more pronounced when it was administered intraperitoneally or combined with radiation.
D000230:Adenocarcinoma / Q000188:drug therapy*; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy; D000328:Adult; D000368:Aged; D001389:Azirines / Q000008:administration & dosage*; D002225:Carbazilquinone / Q000008:administration & dosage* / Q000009:adverse effects; D003536:Cystadenocarcinoma / Q000188:drug therapy; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004715:Endometriosis / Q000188:drug therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010844:Picibanil / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage
D001389:Azirines; D005641:Tegafur; D002225:Carbazilquinone; D010844:Picibanil